1 billion varieties! The third company approved for listing of Hengrui Pharmaceuticals' Pythatan ammonia chloride tablets (I.).

On September 14th, Hengrui Pharmaceuticals 4 classes of generic drug pyrethroma chloride tablets (I.) were approved for listing by the State Drug Administration, becoming the third domestic manufacturer to approve the variety after Baiao Pharmaceuticals and Garden Pharmaceuticals.
Prostatin ammonia chloride tablets originally developed by Novarma, is a single compound tablet composed of angiotensin-stressor antagonist prostatin and calcium ion channel antagonist ammonia chloride, suitable for the treatment of pyrethroid monotherapy or ampicillin monotherapy failed to adequately control blood pressure patients.
the drug, which was first approved by the European Union in 2007/1/15 and is known as Exforge (Chinese: 1000), peaked at $1,456 million in sales and still has $1 billion in global sales in 2019.
is one of the national health insurance Class B varieties, the domestic market size of about 1 billion yuan.
's Rubik's Cube PharmaGo winning database shows that Novarce and Baiao Pharmaceuticals have a winning bid of 7.56 yuan per tablet and 6.71 yuan per tablet, respectively.
domestic manufacturers that have submitted pyrethroma chloride tablets are Huahai Pharmaceuticals, Chengdu Nt and Edia/Alembic Pharmaceuticals, 6 other enterprises.
The prevalence of hypertension in adults in China is about 23.2%, and the number of cases is about 245 million, according to the latest findings of the National Cardiovascular Center.
years, although some progress has been made in the prevention and treatment of hypertension, the overall disease control rate is only about 15.3%, and the status quo of prevention and control is still serious.
single-piece compound preparation is usually composed of two or more anti-stress drugs with different mechanisms of action, because reducing the number of drugs, easy to use, can improve treatment compliance and efficacy, is a new trend of joint treatment, in recent years by Europe and the United States and other multi-country guidelines recommended.
Pharmaceutical Rubik's Cube PharmaGo database shows that there have been a number of single-piece compound preparations such as Ebersatan hydrochlorochloride tablets, pyrethroids (I.), pyrethroid hydrochloride tablets and omestamate hydrochlorin tablets approved in China, and as if through consistency evaluation.
.